Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference
January 23 2019 - 12:00AM
(NYSE American: HEB) — Hemispherx Biopharma Inc.,
an immuno-pharma R&D and emerging commercial growth company
focused on unmet medical needs in immunology, announced today that
CEO Thomas K. Equels will present at NobleConXV — Noble Capital
Markets’ Fifteenth Annual Investor Conference at the W Hotel, Fort
Lauderdale, Fla. — on Tuesday, January 29 at 11:30 a.m. Eastern
Standard Time.
A high-definition, video webcast of the presentation will be
available the following day on the company's website
www.hemispherx.net/link , and as part of a complete catalog of
presentations available at Noble Capital Markets’ Conference
website (http://nobleconference.com) and on the new investor portal
created by Noble called Channelchek (http://www.channelchek.com).
The webcast will be archived on the company's website, the NobleCon
website and on Channelchek.com for 90 days following the event.
Thomas K. Equels, M.S. J.D., chief executive officer of
Hemispherx, will be presenting and meeting one-on-one with
investors. Equels' presentation will focus on immuno-oncology and
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). He
will also discuss how the company is working with several major
cancer research centers with ongoing Phase 1 and Phase 2 clinical
trials combining Ampligen with FDA-approved checkpoint blockade
therapies in several different and highly lethal solid tumors.
Hemispherx current corporate presentation can be found here
http://ir.hemispherx.net/Events_Presentations.
About Noble Capital Markets2019 marks Noble
Capital Markets’ 35th anniversary. The Company is an
equity-research driven, full-service, investment & merchant
banking boutique focused on emerging growth companies. In addition
to NobleCon, Noble hosts numerous “non-deal” corporate road shows
across the United States and Canada. In late 2018, Noble launched
Channelchek.com which features advanced market data,
institutional-quality research, balanced news, videos and podcasts
covering more than 6,000 emerging growth companies. There is no
cost for investors to join. Members: FINRA, SIPC,
MSRB. www.noblecapitalmarkets.com
About Hemispherx Biopharma Hemispherx
Biopharma, Inc. is an immuno-pharma R&D and emerging commercial
growth company focused on unmet medical needs in immunology.
Hemispherx's flagship products include the Argentina-approved drug
rintatolimod (trade names Ampligen® or Rintamod®) and the
FDA-approved drug Alferon N Injection®. Based on results of
published, peer-reviewed pre-clinical studies and clinical trials,
Hemispherx believes that Ampligen® may have broad-spectrum
anti-viral and anti-cancer properties. Clinical trials of Ampligen®
already conducted include studies of the potential treatment of
cancer patients with renal cell carcinoma and malignant melanoma.
These and other potential uses will require additional clinical
trials to generate the safety and effectiveness data necessary to
support regulatory approval. Rintatolimod is a double-stranded RNA
being developed for globally important debilitating diseases and
disorders of the immune system.
Cautionary StatementSome of the statements
included in this press release may be forward-looking statements
that involve a number of risks and uncertainties. Among other
things, for those statements, we claim the protection of the safe
harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. Any forward-looking
statements set forth in this press release speak only as of the
date of this press release. We do not undertake to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. This press release
and prior releases are available at www.hemispherx.net. The
information found on our website is not incorporated by reference
into this press release and is included for reference purposes
only.
Contacts:Hemispherx Biopharma, Inc.Phone:
800-778-4042Email: IR@hemispherx.net
Or
LHA Investor RelationsMiriam Weber MillerSenior Vice
PresidentPhone: +1-212-838-3777Email: mmiller@lhai.com
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From Apr 2024 to May 2024
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From May 2023 to May 2024